Clinical review report: Belimumab (Benlysta) (GlaxoSmithKline Inc.) indication : indicated in addition to standard therapy for reducing disease activity in adult patients with active, autoantibody-positive systemic lupus erythematosus
The objective of this report is to perform a systematic review of the beneficial and harmful effects of belimumab 200 mg/ml subcutaneous injection in addition to standard therapy for reducing disease activity in adult patients with active, autoantibody-positive systemic lupus erythematosus
Corporate Author: | |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2020, June 2020
|
Edition: | Version: Final |
Series: | CADTH common drug review
|
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Table of Contents:
- Includes bibliographical references